Publications

 


  • 168. Measuring disease specific quality of life in localized prostate cancer: The Dutch experience

    Korfage I.J,Essink-Bot M.L,Madalinska J.B,Kirkels W.J,Litwin M.S ,de Koning H.J., 2003

    Journal: Quality of Life Research
    Reference: 12: 459–464

    paper

  • 167. Verification bias and the prostate-specific antigen test — is there a case for a lower threshold for biopsy?

    Schröder FH, Kranse R, 2003

    Journal: N Engl J Med
    Reference: Jul 24;349(4):393-5

    paper

  • 166. Tumor characteristics in a population-based prostate cancer screening trial with prostate-specific antigen

    Mäkinen T, Tammela TL, Hakama M, Stenman UH, Ranniko S, Aro J, Juusela H, Määttanen L, Auvinen A., 2003

    Journal: Clin Cancer Res
    Reference: Jul;9(7):2435-9

    paper

  • 165. Practice of opportunistic PSA screening in the Florence District.

    Zappa M, Visioli C, Crocetti E, Buonamici C, Baccini A, Taddei S, Ciatto S., 2003

    Journal: Eur J Cancer Prev
    Reference: Jun;12(3):201-4

    paper

  • 164. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer

    Draisma G, Boer R, Otto SJ, van der Cruijsen IW, Damhuis RA, Schröder FH, de Koning HJ., 2003

    Journal: JNCI
    Reference: Jun 18;95(12):868-78

    paper

  • 163. Prostate Specific Antigen: appropriate and inappropriate use

    Ciatto S., 2003

    Journal: Recenti Prog Med
    Reference: Mar;94(3):95-8

  • 162. Informed consent for prostate-specific antigen- based screening — European view.

    Ito K, Schröder FH., 2003

    Journal: Urology
    Reference: Jan;61:20-2

    paper

  • 161. Differences in the epidemic rise and decrease of prostate cancer among geographical areas in Southern Europe: an analysis of differential trends in incidence and mortality in France, Italy and Spain.

    Quaglia A, Parodi S, Grosclaude P, Martinez-garcia C, Coebergh JW, Vercelli M, 2003

    Journal: Eur J of Cancer
    Reference: 39:654-665

    paper

  • 160. Guidelines for processing and reporting of prostatic needle biopsies.

    van der Kwast TH, Lopes C, Santonja C, Pihl C-G, Martikainen P, Di Lollo S, Bubendorf L, Hoedemaeker RF, and members of the pathology committee of the ERSPC., 2003

    Journal: J. Clin Path
    Reference: 56:336-40

  • 159. Screening for Prostate Cancer.

    Schröder FH, 2003

    Journal: Urolclin North Am.
    Reference: 30(2):239-51

  • 158. Standardization of two immunoassays for human glandular kallikrein 2.

    Haese A, Vaisanen V, Finlay JA, Pettersson K, Rittenhouse HG, Partin AW, Bruzek DJ, Sokoll LJ, Lilja H, Chan DW., 2003

    Journal: Clin. Chem
    Reference: Apr;49(4):601-10

    paper

  • 157. Should we start population screening for prostate cancer? Randomised trials are still needed.

    Auvinen A, Alexander FE, de Koning HJ, Miller AB., 2002

    Journal: Int J Cancer
    Reference: Jan 20;97(3):377-8

    paper

  • 156. Does PSA screening reduce prostate cancer mortality?

    Vis AN, 2002

    Journal: JAMC
    Reference: 166(5):600-1

    paper

  • 155. Serendipity in detecting disease in low prostate-specific antigen ranges.

    Vis A.N, Kranse R, Roobol M, Schröder F.H, van der Kwast Th., 2002

    Journal: BJU int.
    Reference: Mar;89(4):384-389.

    paper

  • 154. Value of tissue markers p27(kip1), MIB-1, and CD44s for the pre-operative prediction of tumour features in screen-detected prostate cancer.

    Vis A.N, van Rhijn B.W, Noordzij M.A, Schröder F.H, van der Kwast Th., 2002

    Journal: J. Pathol.
    Reference: Jun; 197(2):148-154

    paper

  • 153. A more advanced clinical stage is positively correlated with an increased prostate cancer detection rate.

    Roobol MJ, Kranse R, Van der Cruijsen I, Schröder FH., 2002

    Journal: Urology
    Reference: 59(1)91-96

    paper

  • 152. Large-scale randomized prostate cancer screening trials: program performances in the ERSPC- and PLCO-trials (European Randomized Study of Screening for Prostate Cancer and Prostate, Lung, Colorectal and Ovary cancer trials).

    Koning de HJ, Auvinen A, Berenguer-Sanchez A, Calais da Silva f, Ciatto S, Denis J, Gohagan J, Hakama M, Hugosson J, Kranse R, Nelen V, Prorok PC, Schröder FH., 2002

    Journal: Int. J Cancer
    Reference: 97(2):237-244.

    paper

  • 151. Prostate Cancer mortality reduction by screening: power and time frame with complete enrollment in the European Randomized Study of Screening for Prostate Cancer (ERSPC) trial.

    Koning de HJ, Liem MK, Baan CA, Boer R, Schröder FH, Alexander FE on behalf of ERSPC., 2002

    Journal: Int J Cancer
    Reference: 98:268-273

    paper

  • 150. Who should be biopsied in prostate cancer screening? Estimation of prostate cancer risk on the basis of total and free prostate-specific antigen, prostate volume and digital rectal examination.

    Finne P, Auvinen A, Aro J, Juusela H, Määttänen L, Ranniko S, Hakama M, Tammela T, Stenman UH., 2002

    Journal: Eur. Urol.
    Reference: 41:619-627

    paper

  • 149. Determining the sensitivity of transrectal ultrasonography on a consecutive series of prostate cancers in a clinical and screening setting.

    Ciatto S, Bonardi R, Lombardi C, Zappa M, Gervasi G., 2002

    Journal: Tumori
    Reference: Jul-Aug;88(4):281-3

  • 148. Complication rates and risk factors of 5802 transrectal ultrasound guided sextant biopsies of the prostate within a population-based screening program.

    Raaijmakers R, Kirkels W.J, Roobol M.J, Wildhagen M, Schröder F.H., 2002

    Journal: Urology
    Reference: 60(5):826-830

    paper

  • 147. Acceptability and complications of prostate biopsy in population based PSA screening versus clinical practice: a prospective controlled study.

    Mäkinen T, Auvinen A, Hakama M, Stenman U-H, Tammela T.L.J., 2002

    Journal: Urology
    Reference: 60(5):846-850

    paper

  • 146. Different PSA assays lead to detection of prostate cancers with identical histological features.

    Yurdakul G, Bangma C.H, Blijenberg B.G, van Zelst B.D, Wildhagen M.F, van der Kwast Th.H, Schröder F.H., 2002

    Journal: Eur. Urol
    Reference: 42, 154-158

    paper

  • 145. Family history and prostate cancer screening with prostate specific antigen.

    Mäkinen T, Tammela T.L.J, Stenman U-H, Määttänen L, Rannikko S, Aro J, Juusela H, Hakama M, Auvinen A., 2002

    Journal: J. Clin Oncol
    Reference: 20(11):2658

    paper

  • 144. Analysis of PSA velocity in 1666 healthy subjects undergoing total PSA determination at two consecutive screening rounds.

    Ciatto S, Bonardi R, Lombardi C, Zappa M, Gervasi G, Cappelli G., 2002

    Journal: Int. J. Biol Markers
    Reference: 17 (2): 79-83

  • 143. Lead-time in prostate cancer screening (Finland).

    Auvinen A, Määttänen L, Stenman U-H, Tammela T, Ranniko S, Aro J,Juusela H, Hakama M., 2002

    Journal: Cancer causes and control
    Reference: 13:279-285

    paper

  • 142. The clinical utility of the prostate specific membrane antigen reverse-transcription/polymerase chain reaction to detect circulating prostate celss: an analysis in healthy men and women.

    Llanes L, Ferrulo A, Paez A, Gomez J.M, Moreno A, Berenguer A., 2002

    Journal: BJUI
    Reference: 89: 882-885

    paper

  • 141. Polyphenols in red wine inhibit the proliferation and induce apoptosis of LNCaP cells

    Romero I, Paez A, Ferrulo A, Lujan M, Berenguer A., 2002

    Journal: BJUI
    Reference: 89: 950-954

    paper

  • 140. PSA-use in a Spanish industrial area.

    Paez A, Lujan M, llanes L, Ronero I, Angel de la Cal M, Miravallis E, Berenguer A., 2002

    Journal: Eur. Urology
    Reference: 41 : 162-166

    paper

  • 139. Health-related quality of life and cost-effectiveness studies in the ERSPC and the US PLCO.

    Miller AB, Madalinska J, 2001

    Journal: Eur.J.off Cancer
    Reference: 37:2154-60

    paper

  • 138. Validity of the prostate specific antigen test for prostate cancer screening: followup study with a bank of 21,000 sera in Finland.

    Hakama M, Stenman U-H, Aromaa A, Leinonen J, Hakulinen T, Knekt P., 2001

    Journal: J. of Urology
    Reference: 166, 2189-2192

    paper

  • 137. PSA based early detection of prostate cancer – Validation of screening without rectal examination.

    Schröder FH, Roobol-Bouts M, Vis AN, Kwast TH van der, Kranse R., 2001

    Journal: Urology
    Reference: 57:83-90

    paper

  • 136. De bepaling van totaal PSA m.b.v. de ACS: 180 in perspectief. Ned.

    Zelst BD van, Blijenberg BG, Schröder FH., 2001

    Journal: Tijdschr. Klin. Chemie
    Reference: 26:3-8.

  • 135. Cytogenetic Analysis of Prostatic Adenocarcinomas from Screening Studies: Early Cancers May Contain Aggressive Genetic Features.

    Alers JC, Krijtenburg PJ, Vis AN, Hoedemaeker RF, Wildhagen MF, Hop WC, Kwast TH van der, Schröder FH, Tanke HJ, van Dekken H. Molecular, 2001

    Journal: Am J Pathol
    Reference: 158(2):399-406.

    paper

  • 134. Health-related quality of life in patients with screen-detected versus clinically diagnosed prostate cancer preceding primary treatment.

    Madalinska JB, Essink-Bot ML, de Koning HJ, Kirkels WJ, van der Maas PJ, Schröder FH., 2001

    Journal: The Prostate
    Reference: 46(2):87-97.

    paper

  • 133. Categorization of prostate cancers according to previously established criteria.

    Vis AN, Hoedemaeker RF, van der Kwast Th, Schröder FH., 2001

    Journal: The Prostate
    Reference: 46(2):154-162.

  • 132. Health-related Quality-of-Life effects of radical prostatectomy and primary radiotherapy for screen-detected of clinically diagnosed localized prostate cancer..

    Madalinska JB, Essink-Bot ML, de Koning HJ, Kirkels WJ, van der Maas PJ, Schröder FH., 2001

    Journal: J Clin Oncol
    Reference: 19(6):1619-28

    paper

  • 131. Predictors of biological aggressiveness of prostate specific antigen screening detected prostate cancer.

    Isola J, Auvinen A, Poutiainen M, Kakkola L, Järvinen TAH, Määttänen L, Stenman UH, Tammela T, Hakam M, Visakorpi T., 2001

    Journal: J. of Urology
    Reference: 165:1569-74.

    paper

  • 130. Three-year results of the Finnish Prostate Cancer Screening Trial.

    Määttänen L, Auvinen A, Stenman UH, Tammela T, Rannikko S, Aro J, Juusela H, Hakama M., 2001

    Journal: JNCI
    Reference: 93(7):552-3.

    paper

  • 129. The independent prognostic value of comorbidity among men aged < 57 years with localized prostate cancer: a population-based study

    Post PN, Hansen BE, Kil PJM, Janssen-Heijnen MLG, Coebergh JWW, 2001

    Journal: BJUI
    Reference: 87,821-826

  • 128. Tumor characteristics in screening for prostate cancer with and without rectal examination as an initial screening test at low PSA (0.0 – 3.9 ng/ml).

    Vis AN, Hoedemaeker RF, Roobol M, Kwast van der ThH, Schröder FH., 2001

    Journal: The Prostate
    Reference: 47:252-61.

    paper

  • 127. Prostatic intraepithelial neoplasia and putative precursor lesions of prostate cancer: a clinical perspective.

    Vis AN, Kwast van der ThH., 2001

    Journal: BJUI
    Reference: 88:147-157.

    paper

  • 126. The predictive value for prostate cancer of lesions that raise suspicion of concomitant carcinoma. An evaluation from a randomized, population-based study of screening for prostate cancer.

    Vis AN, Hoedemaeker RF, Roobol M, Schröder FH, Kwast van der ThH., 2001

    Journal: Cancer
    Reference: 92(3):524-34.

    paper

  • 125. Pathologic features of prostate cancer found at population-based screening with a four-year interval.

    Hoedemaeker RF, van der Kwast ThH, Boer R, de Koning HJ, Roobol M, Vis AN, Schröder FH., 2001

    Journal: JNCI
    Reference: 93(15):1153-8.

    paper

  • 124. The value of current diagnostic tests in prostate cancer screening.

    Van der Cruijsen-Koeter IW, Wildhagen MF, de Koning HJ, Schröder FH., 2001

    Journal: BJUI
    Reference: 88:458-466

    paper

  • 123. Discordant performance of assays for free and total prostate-specific antigen in relation to the early detection of prostate cancer.

    Blijenberg BG, Yurdakul G, van Zelst BD, Bangma CH, Wildhagen MF, Schröder FH., 2001

    Journal: BJUI
    Reference: 88:545-550

    paper

  • 122. Predicting prostate biopsy outcome by findings at digital rectal examination, Transrectal ultrasonography, PSA, PSA density and free- to- total PSA ratio in a population based screening setting.

    Ciatto S, Bonardi R, Lombardi C, Cappelli G, Castagnoli A, DAgata A, Zappa M, Gervasi G, 2001

    Journal: Int. J. Biol Markers
    Reference: 16: 179- 182.

  • 121. Prostate cancer screening within a prostate specific antigen range of 3 to 3.9 ng./ml.: a comparison of digital rectal examination and free prostate Specific antigen as supplemental screening tests.

    Mäkinen T, Tammela TL, Hakama M, Stenman UH, Rannikko S, Aro J, Juusela H, Määttänen L, Auvinen A., 2001

    Journal: J Urol
    Reference: 166(4):1339-42

    paper

  • 120. Randomized screening trial for prostate cancer in Finland.

    Hakama M, Aro J, Auvinen A, Juusela H, Määttänen L, Stenman UH, Tammela TL., 2001

    Journal: Eur Urol.
    Reference: 39 (suppl 4):32

    paper

  • 119. Prostate cancer screening.

    Finne P, Auvinen A, Stenman UH., 2001

    Journal: Lancet.
    Reference: 357(9263):1201(letter)

    paper

← PreviousNext →